Last Updated: 19 Sep 2024
Executive Summary
TC BioPharm Holdings PLC (TCBP) is a clinical-stage biopharmaceutical company focused on developing immunotherapy products based on its gamma delta allogeneic T-cell platform. The company has a market capitalization of $3.8 million and is currently trading at $6.65 per share. TCBP has a strong pipeline of product candidates, including its lead candidate, TC-210, which is being evaluated in a Phase II clinical trial for the treatment of relapsed/refractory acute myeloid leukemia (AML). The company has a number of potential catalysts on the horizon, including data from the TC-210 Phase II trial expected in 2024.
Company Overview
TC BioPharm was founded in 2006 and is headquartered in Motherwell, UK. The company's mission is to develop and commercialize innovative immunotherapies that target cancer and other diseases. TCBP's gamma delta allogeneic T-cell platform is a novel approach to immunotherapy that has the potential to overcome some of the limitations of traditional T-cell therapies.
Fundamental Analysis
TCBP is a clinical-stage company with no revenue. The company's financial performance has been mixed in recent quarters. In the first nine months of 2023, TCBP reported a net loss of $12.9 million, compared to a net loss of $10.3 million in the same period of 2022. The company's cash and cash equivalents were $25.3 million as of September 30, 2023.
TCBP's financial performance is expected to improve in the coming years as the company advances its clinical pipeline. The company's lead candidate, TC-210, is expected to enter Phase III clinical trials in 2024. If TC-210 is successful in clinical trials, it could be a major commercial success for TCBP.
Technical Analysis
TCBP's stock price has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also below 50, indicating that the stock is oversold.
The technical analysis suggests that TCBP's stock price could continue to decline in the short term. However, the stock could rebound if the company reports positive data from its clinical trials.
Short Term Outlook
TCBP's stock price is expected to be volatile in the short term. The stock could decline further if the company reports negative data from its clinical trials. However, the stock could rebound if the company reports positive data or if there is a positive development in the immunotherapy space.
Long Term Outlook
TCBP's long-term outlook is positive. The company has a strong pipeline of product candidates and a number of potential catalysts on the horizon. If TCBP's clinical trials are successful, the company could be a major player in the immunotherapy space.
Analyst Recommendations
TCBP is currently rated as a Buy by one analyst. The analyst has a price target of $140 per share. The analyst believes that TCBP's gamma delta allogeneic T-cell platform has the potential to be a major breakthrough in the treatment of cancer.
